Boehringer Ingelheim Animal Health: Can AI Help Veterinary R&D Find Better Medicines With Fewer Animal Studies?

Overview: How Boehringer Ingelheim Animal Health’s AI-Driven End-to-End Drug Discovery Platform Transforms Veterinary R&D

Boehringer Ingelheim Animal Health's internal, AI-enabled drug-discovery and digital-science capability applies machine learning, generative AI, predictive modelling, and integrated R&D data to support veterinary therapeutic research. It addresses the long timelines, high experimental burden, and uncertainty associated with finding and optimising candidates for animal-health conditions across companion animals, horses, and livestock. Its public materials describe a Design Hub containing more than 100 proprietary software solutions, alongside the internally developed Advanced Design Assistant for Molecules (ADAM), which uses the company’s substance library and published research literature to generate and prioritise molecular-design ideas.

The underlying approach combines historical chemical and biological data from a central database with computational models that estimate molecular potency and pharmacokinetic characteristics. Researchers can use these outputs to compare multiple design variables, prioritise candidate compounds, and refine molecules before committing to more resource-intensive laboratory studies. Boehringer Ingelheim reports that this workflow can shift aspects of molecule redesign from hours, days, or weeks of laboratory work to computational analysis performed in seconds, while noting that human scientific expertise remains essential, particularly where data are limited or genuinely novel biology is involved.

For veterinary R&D workflows, the intended value is faster data analysis and more targeted candidate selection, with the potential to reduce the number of molecules synthesised and the volume of downstream experimental testing. The company also states that these data-driven methods can reduce environmental footprint and animal-testing demand; realised benefits will vary by therapeutic area, target biology, dataset quality, model performance, and the experimental validation required for each programme.

Last checked on September 30, 2026: Boehringer Ingelheim Animal Health remains active, with its AI-enabled canine-cardiology solution Eko Vet+™ | CANINEBEAT® AI reported as launched in the United States, United Kingdom, and Germany during 2026.

What is Boehringer Ingelheim Animal Health?

Boehringer Ingelheim Animal Health is a veterinary-health business that uses internal digital-science tools, machine learning, and generative AI to support animal-health drug discovery, candidate prioritisation, diagnostics, and monitoring. Its AI-enabled R&D environment includes a proprietary Design Hub of more than 100 software solutions and the ADAM molecular-design assistant, which draws on internal substance data and published literature to generate and evaluate candidate ideas for veterinary research. It serves veterinarians, animal-health researchers, farmers, and pet or horse owners through products and digital collaborations; the company’s public materials describe internal research capabilities rather than a separately purchasable AI platform, and do not specify product-level regulatory or compliance certification for the internal AI tools.

Intended Use and Limitations

• Boehringer Ingelheim Animal Health is part of the privately held Boehringer Ingelheim group and operates veterinary medicines, vaccines, diagnostics, and digital-health initiatives across global animal-health markets.

• Boehringer Ingelheim partnered with Eko Health in 2025 to combine canine cardiology expertise with Eko’s digital stethoscope and AI technology for heart-murmur detection in dogs.

• The Eko collaboration led to Eko Vet+™ | CANINEBEAT® AI, a canine-specific AI auscultation solution that Boehringer reports as launched in the United States, United Kingdom, and Germany in 2026.

• Boehringer Ingelheim formed a global commercial partnership with Sleip and became a shareholder in the company to expand AI-supported lameness detection, diagnosis, and treatment workflows for horses.

• Boehringer Ingelheim acquired Saiba Animal Health in 2024, adding a therapeutic-vaccine technology platform and pipeline for companion-animal R&D.

• In August 2026, Boehringer Ingelheim acquired Swiss equine-health biotechnology company Evax AG to expand its therapeutic-vaccine pipeline for horses; transaction terms were not disclosed.

• Boehringer Ingelheim Animal Health UK Limited’s Pirbright biological-manufacturing site holds a UK Veterinary Medicines Directorate GMP compliance certificate following a 2024 inspection; this is site-specific manufacturing compliance, not certification of its AI tools.

• Boehringer Ingelheim states that it processes personal data in accordance with GDPR and applicable local law, including use of contractual safeguards for relevant international data transfers.

• The company publicly describes internal AI and digital-science research capabilities, including the ADAM molecular-design system and a Design Hub of proprietary research software; these are internal capabilities rather than a separately specified external AI-platform certification.